Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

Spruce Biosciences, Inc. SPRB

Set alert

Price alert · SPRB

All alert types
44.11 USD -0.45 -1.00%

As of Nov 3, 10:10 AM ET

Bid
43.92 × 2
Ask
45.11 × 2
44.32 Day range 45.27
38.06 52-week range 129.00
YTD
-49.37%
1 year
-57.89%
Open
45.27
Prev close
44.55
Mkt cap
127.49M
Vol
6.49K
Avg vol
82.43K
EPS
-39.12
P/E
0.00
Div yield
0.00%
More statistics
Low
44.32
High
45.27
Forward P/E
-0.41
Beta
0.00
Short ratio
0.10
Inst. own
46.69%
Dividend
0.00
Ex-div date
Earnings
Aug 12, 2024
50-d avg
0.50446
200-d avg
0.668845
1y target
1.83

6M chart

Chart tools
Interval
1m5m15m30m

Signals (15)
NameDateAgo
MACD: Buy SignalOct 21, 20261 week ago
RSI: OversoldOct 14, 20262 weeks ago
SMA: BearishSep 22, 20261 month ago
SMA: BearishSep 22, 20261 month ago
MACD: Sell SignalSep 4, 20262 months ago
SMA: BullishAug 24, 20262 months ago
RSI: OverboughtAug 24, 20262 months ago
SMA: BullishAug 13, 20262 months ago
MACD: Buy SignalAug 4, 20263 months ago
MACD: Sell SignalJul 8, 20263 months ago
SMA: BearishJul 1, 20264 months ago
SMA: BullishJun 26, 20264 months ago
MACD: Buy SignalJun 4, 20265 months ago
MACD: Sell SignalMay 18, 20265 months ago
MACD: Buy SignalMay 6, 20266 months ago

Analyst view

Consensus: hold

Hold
Price target (mean) 1.83 -95.8% downside
Target (low)
1.00
Target (mean)
1.83
Target (high)
3.00
Ratings (0m) 5 0 buy · 5 hold · 0 sell
  • Strong buy0
  • Buy0
  • Hold5
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 5
  • 1 month ago 5
  • 2 months ago 5

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

SPRB analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.205-0.25 – -0.16-0.23+10.9%885.00K-69.3%4
Next quarter-0.19667-0.22 – -0.17-0.28+29.8%500.00K-75.0%3
Current year-0.93-0.99 – -0.87-1.24+25.0%5.09M-49.5%4
Next year-0.6375-0.92 – -0.27-0.93+31.4%1.60M-68.6%4

Upgrades and downgrades

The latest rating changes

SPRB analyst upgrades and downgrades
DateFirmActionFromTo
Dec 16, 2024HC Wainwright & Co.ReiteratedNeutralNeutral
Dec 12, 2024GuggenheimReiteratedNeutralNeutral
Dec 11, 2024JMP SecuritiesDowngradeMarket OutperformMarket Perform
Dec 11, 2024RBC CapitalReiteratedSector PerformSector Perform
Dec 11, 2024OppenheimerDowngradeOutperformPerform
Nov 12, 2024RBC CapitalReiteratedSector PerformSector Perform
Aug 19, 2024HC Wainwright & Co.Reiterated—Neutral
Aug 13, 2024RBC CapitalReiteratedSector PerformSector Perform
Jun 13, 2024OppenheimerMaintainedOutperformOutperform
Jun 5, 2024HC Wainwright & Co.Reiterated—Neutral
May 14, 2024HC Wainwright & Co.Reiterated—Neutral
Mar 14, 2024RBC CapitalDowngradeOutperformSector Perform
Mar 14, 2024HC Wainwright & Co.DowngradeBuyNeutral
Mar 14, 2024Leerink PartnersDowngradeOutperformMarket Perform
Mar 14, 2024JMP SecuritiesMaintainedMarket OutperformMarket Outperform
Mar 14, 2024Ladenburg ThalmannDowngradeBuyNeutral
Mar 14, 2024GuggenheimDowngradeBuyNeutral
Mar 5, 2024RBC CapitalReiteratedOutperformOutperform
Feb 26, 2024RBC CapitalMaintainedOutperformOutperform
Feb 21, 2024GuggenheimInitiated—Buy
Nov 20, 2023HC Wainwright & Co.ReiteratedBuyBuy
Sep 13, 2023RBC CapitalReiteratedOutperformOutperform
Sep 13, 2023HC Wainwright & Co.ReiteratedBuyBuy
Sep 8, 2023SVB LeerinkUpgradeMarket PerformOutperform
Aug 18, 2023OppenheimerMaintainedOutperformOutperform
Aug 18, 2023HC Wainwright & Co.ReiteratedBuyBuy
Aug 16, 2023JMP SecuritiesMaintainedOutperformOutperform
Aug 15, 2023RBC CapitalReiteratedOutperformOutperform
Jun 13, 2023HC Wainwright & Co.ReiteratedBuyBuy
May 23, 2023OppenheimerReiteratedOutperformOutperform